Review Article
Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Figure 1
Pooled analysis of 1,861 ipilimumab-treated patients from 12 clinical trials [3]. Median overall survival was 11.4 months (95% CI: 10.7–12.1 months) and 3-year overall survival was 22% (95% CI: 20–24%).